Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational study

Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational study - Efficacy of ICI in patients with NSCLC other than adenocarcinoma or squamous cell carcinoma in a multi-center retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037777

Enrollment

Registered

2019-08-22

Start date

2019-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who had unresectable non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma, and all patients received with immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: Patients with no or insufficient clinical information

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactKoichi Miyashita

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

miya501@hama-med.ac.jp053-435-2263

Outcome results